The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Examples of biology informing treatment decisions in CLL
Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thermi, Greece, discusses how a greater understanding of disease biology can inform treatment decisions in chronic lymphocytic leukemia (CLL), including ribosomal profiling of patients treated with ibrutinib as well as the significance of aberrant p53 signalling in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
